Search clinical trials for: PK and Safety Study of Spinosad

Total 493039 results

Ono Pharmaceutical Co. Ltd

Completed

Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects

Healthy Volunteers

Japan
Ono Pharmaceutical Co. Ltd

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

Healthy Volunteers

Japan
SFJ Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

Healthy

United States
BenevolentAI Bio

Completed

Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.

Healthy Volunteer Study

United Kingdom
UCB Biopharma SRL

Completed

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Healthy Study Participants

United States
Seres Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Allogeneic Hematopoietic Stem Cell Transplantation

United States
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Acute Ischemic Stroke

China
Luye Pharma Group Ltd.

Active, not recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Osteoporosis, Postmenopausal

Poland, United States, Czechia, Bulgaria, Japan
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Acute Ischemic Stroke

China
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

Advanced Melanoma

United States, Spain, Belgium, Australia, Germany, United Kingdom
Peptomyc S.L.

Terminated

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure)

Pancreatic Cancer | Advanced Solid Tumors | CRC

Spain
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin UK, Ltd.

Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Multiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's Lymphoma

United Kingdom
Visterra, Inc.

Terminated

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

Autoimmune Diseases

New Zealand, Germany, Bulgaria, Moldova, Republic of, Netherlands
Pfizer

Completed

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Arthritis Juvenile Idiopathic

United States, Belgium, Spain, Canada, Mexico, Turkey, Israel, China, Slovakia, Hungary, India, Argentina, Brazil, Germany, South Africa, Poland, Ukraine, Italy, Costa Rica, Russian Federation, United Kingdom
Shanghai Henlius Biotech

Active, not recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Multiple Myeloma

China
Shanghai Henlius Biotech

Active, not recruiting

A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

Solid Tumor and Lymphoma

China
Spero Therapeutics
United States Department of Defense

Completed

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

Renal Impairment

New Zealand
TJ Biopharma Co., Ltd.

Terminated

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Pfizer

Terminated

PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects

Gastroesophageal Reflux Disease

United States, Bosnia and Herzegovina, Slovakia, Italy, Germany, Argentina, Georgia, Serbia, Ukraine
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (POLARGO)

Diffuse Large B-Cell Lymphoma

United States, United Kingdom, Korea, Republic of, Finland, Brazil, China, Mexico, Canada, Germany, India, Turkey, Greece, Italy, Spain, France, Ireland
AstraZeneca

Completed

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors

Spain, United States, Canada
Amicus Therapeutics

Active, not recruiting

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Pompe Disease

United States, Netherlands, United Kingdom, Australia, Germany, New Zealand
NextCure, Inc.

Terminated

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Advanced or Metastatic Solid Tumors

United States
Hektoen Institute for Medical Research
National Institute of Mental Health (NIMH)

Completed

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

HIV/AIDS | Gender | Behavior and Behavior Mechanisms

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Epizyme, Inc.
Celgene

Completed

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

Acute Myeloid Leukemia | Myeloproliferative Disorders | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Germany, Netherlands
GlaxoSmithKline

Completed

A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

Pain, Inflammatory

United Kingdom, Germany, Poland
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

IPF

United States
Antabio

Completed

FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects

Healthy Volunteers

France
Rivus Pharmaceuticals, Inc.

Active, not recruiting

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF (HFpEF)

Heart Failure With Preserved Ejection Fraction

United States
Lyndra Inc.

Completed

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

Schizophrenia | Schizoaffective Disorder

United States
NextCure, Inc.

Completed

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Melanoma | Breast Cancer | Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Advanced or Metastatic Solid Tumors | CRC

United States
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Completed

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Tetanus

China
Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Acute Myeloid Leukemia

Italy, Croatia, Estonia, Czechia, France, Spain, Sweden, Bulgaria, Lithuania, Serbia, Hungary, Finland, Norway, Romania, Slovakia
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Hoffmann-La Roche

Terminated

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis

United States, Hungary, Georgia, Moldova, Republic of, Ukraine
AdAlta Limited

Completed

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

Chronic Kidney Diseases | Interstitial Lung Disease

Australia
AltruBio Inc.
ICON plc

Completed

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Healthy Volunteers

United States
Crinetics Pharmaceuticals Inc.

Active, not recruiting

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of Pancreas

United States, Brazil, Argentina, Canada, Mexico, Peru, Poland
Oneness Biotech Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

Atopic Dermatitis

United States
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria (PEGASUS)

Phenylketonuria (PKU)

United States, Germany
SFJ Pharmaceuticals, Inc.
SFJ Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Healthy

China
Neutrolis

Terminated

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

Covid19

Austria, Ukraine
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Non-alcoholic Steatohepatitis (NASH)

United States
Ensoma

Completed

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

Healthy | Renal Insufficiency

United States
Cytokinetics

Completed

Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM (REDWOOD-HCM)

Hypertrophic Cardiomyopathy (HCM)

United States, Spain, Italy, Netherlands
NextCure, Inc.

Terminated

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Gastric Cancer | Ovarian Cancer | Colo-rectal Cancer | Advanced or Metastatic Solid Tumors

United States
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
Syneos Health
CuraTeQ Biologics Private Ltd.

Completed

Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

Healthy Volunteers

New Zealand, Australia

3

Subscribe